AusperBio Secures $50 Million for Groundbreaking Hepatitis B Cure
AusperBio Therapeutics, Inc and Ausper Biopharma Co., Ltd are at the forefront of clinical innovations aimed at providing a functional cure for chronic hepatitis B (CHB). Recently, the company announced that it has successfully closed a Series B+ financing round, amassing a remarkable USD $50 million. This round was led by an established venture capital firm with robust contributions from notable investors such as Qiming Venture Partners, CDH Investments, and more.
Significance of the Funding
This recent funding marks a significant milestone for AusperBio, showcasing the strong confidence investors have in their promising lead product and strategic focus. The capital raised will play a crucial role in advancing the clinical development of AHB-137, a new antisense oligonucleotide specifically designed to combat CHB. With plans for Phase II trials beyond mainland territories, these funds will also facilitate partnerships in commercial manufacturing and expand the company's pipeline for long-term growth.
Statements from Leadership
Dr. Guofeng Cheng, co-founder and CEO, expressed immense gratitude for the unwavering support from investors, noting, "This funding will propel us forward as we transition AHB-137 into the next phase of international development, reinforcing our commitment to a functional cure for chronic hepatitis B.” Meanwhile, Dr. Chris Yang, the co-founder and CSO, highlighted the importance of the recent Phase IIb results, further motivating the AusperBio team to pursue innovative treatment solutions for CHB.
Innovative Approach with AHB-137
AHB-137 utilizes AusperBio's proprietary Med-Oligo™ ASO technology platform, aiming to deliver a groundbreaking functional cure for chronic hepatitis B. Early clinical developments have yielded encouraging results, with findings presented at prominent medical gatherings like EASL and AASLD. Having successfully wrapped up its Phase 1b trials, AHB-137 is gearing up for multiple Phase 2 studies, demonstrating AusperBio’s commitment to a strategic global development framework.
Transforming Treatment Paradigms
With a dedicated mission, AusperBio strives to bring innovative, patient-centric solutions to the healthcare landscape. By targeting the comprehensive challenges linked to chronic hepatitis B, AusperBio is enhancing overall treatment paradigms and making strides toward diminishing the global health burden associated with this condition.
About AusperBio
As a clinical-stage biopharmaceutical company, AusperBio focuses on the advancement of oligonucleotide therapies and targeted delivery systems. Supported by their proprietary Med-Oligo™ ASO platform, which enhances traditional ASO treatments, AusperBio aims to treat various diseases through innovative designs. The company's ongoing commitment to transformative therapies underscores their vision of a healthier future.
Frequently Asked Questions
What is AusperBio's primary focus?
AusperBio is dedicated to advancing oligonucleotide therapies to achieve a functional cure for chronic hepatitis B.
How much funding has AusperBio raised recently?
AusperBio has raised $50 million in its recent Series B+ financing round.
What is AHB-137?
AHB-137 is a novel unconjugated antisense oligonucleotide aimed at providing a functional cure for chronic hepatitis B.
What are AusperBio's future plans for AHB-137?
The company intends to advance AHB-137 through Phase II trials and scale up manufacturing capabilities.
How is AusperBio impacting chronic hepatitis B treatment?
AusperBio's dedication to innovative research promises to disrupt traditional treatment paradigms and offer new options for patients suffering from chronic hepatitis B.
